NYSE:HIMSHealthcare
Hims & Hers Health (HIMS) Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path
Hims & Hers Health (HIMS) has restarted its collaboration with Novo Nordisk, bringing FDA-approved GLP-1 drugs like Wegovy and Ozempic back to its platform alongside a new subscription based weight loss membership program.
See our latest analysis for Hims & Hers Health.
The latest 1 day share price return of 6.22% to US$20.33 extends a 7 day gain of 8.25% and a 1 month share price return of 29.16%. This follows a 90 day share price decline of 42.67% and a 1 year total shareholder return of...